Management of Acute Upper Respiratory Tract Infection: Role of Early Intervention
Article Sidebar
Main Article Content
Abstract
Acute upper respiratory tract infections (URTIs) are caused by viral or bacterial infections of the nose, sinuses, pharynx, and larynx. The majority of acute URTIs are usually short-term and self-limiting with mild symptoms. However, in some cases, it can lead to serious complications and socioeconomic problems for both individuals and society. Treatments for acute URTIs are mainly symptom-based for example decongestant drugs and nasal congestion relief, antihistamine or antiallergy, antipyretic such as paracetamol, oral nonsteroidal anti-inflammatory drugs, expectorant, antitussive, etc. The technologies for early intervention to prevent worsening symptoms are limited. Currently, innovative polymer nasal sprays are in clinical studies to show their efficacy when used for early intervention of acute upper respiratory tract infections. These sprays trap various virus particles to protect viral penetration in tissues to reduce severity and infection. Hence, an innovative polymer nasal spray to reduce the severity and duration of URTIs can add benefit to current treatments.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The content and information in articles published in the PCFM journal are solely the opinions and responsibilities of the authors. The journal's editorial board does not necessarily agree with or share any responsibility for them.
All articles, information, content, images, etc., published in the PCFM journal are the copyright of the PCFM journal. If any individual or organization wishes to reproduce, distribute, or use any part or the entirety of the content, they must obtain written permission from the PCFM journal beforehand.
References
Wang DY, Eccles R, Bell J et al. Management of acute upper respiratory tract infection: the role of early intervention. Expert Rev Respir Med. 2021 Dec; 15(12): 1517 – 1523.
Heikkinen T, Järvinen A. The common cold. Lancet. 2003 Jan; 361 (9351): 51 –59.
Grief SN. Upper Respiratory Infections. Prim Care. 2013 Sep; 40(3): 757 – 770.
Turner RB. The common cold. Goldman’s Cecil Med. 2012: 2089 – 91.
Winther B, Gwaltney JM Jr, Mygind N, et al. Viral Induced Rhinitis. Am J Rhinol. 1998 Jan;12(1): 17 – 20.
Linder JA, Singer DE. Health-related quality of life of adults with upper respiratory tract infections. J Gen Intern Med. 2003 Oct; 18(10): 802 – 807.
Thomas M, Bomar PA. Upper respiratory tract infection. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2022 Jan.
Meneghetti A. Upper respiratory tract infection [Internet]. Medscape; 2020 [cited 2022 March 3]. Available from: https://emedicine.medscape.com/article/302460-overview.
Cough and cold remedies for the treatment of acute respiratory infections in young children 2001 [Internet]. World Health Organization [cited 2022 March 3]. Available from: https://apps.who.int/iris/handle/10665/66856.
Pratter MR. Cough and the common cold: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan; 129 (1Suppl): 72S – 74S.
Virgincar N, Spencer R. Current management options for upper respiratory tract infection. Prescriber. 2006 Jan; 17(1): 16 –23.
Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005 Nov; 5(11): 718 – 725.
Witek TJ, Ramsey DL, Carr AN, et al. The natural history of community- acquired common colds symptoms assessed over 4-years. Rhinology. 2015 Mar; 53(1): 81 – 88.
Papadopoulos NG, Megremis S, Kitsioulis NA, et al. Promising approaches for the treatment and prevention of viral respiratory illnesses. J Allergy Clin Immunol. 2017 Jul; 140(4): 921 –932.
Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011 Jan; 31(1): 42 – 92.
Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012 Feb; 156(7): 512 – 524.
Moraga-Espinoza D, Warnken Z, Moore A, et al. A modified USP induction port to characterize nasal spray plume geometry and predict turbinate deposition under flow. Int J Pharm. 2018 Sep; 548 (1): 305 – 313.
Shin Y, Kokate R, Desai V, et al. D-cycloserine nasal formulation development for anxiety disorders by using polymeric gels. Drug Discov Ther. 2018; 12(3): 142 – 153.
Pandey P, Cabot PJ, Wallwork B, et al. Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - A platform for therapeutic delivery to mucosal sinus tissue. Eur J Pharm Sci. 2017 Jan; 96: 499 – 507.
Braga PC, Alfieri M, Dal Sasso M, et al. Visual evaluation of binding to mucosal cells of a medical device against the common cold. Drug Dev Ind Pharm. 2008 May; 34(5): 459 – 64.
Cook SL, Bull SP, Methven L, et al. Mucoadhesion: a food perspective. Food Hydrocoll. 2017 Nov; 72: 281 – 296.
Leibbrandt A, Meier C, König-Schuster M, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010 Dec; 5 (12): e14320.
Grassauer A, Weinmuellner R, Meier C, et al. Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008 Sep; 5: 107.
Hull D, Rennie P, Noronha A et al. Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold. Acta Otorhinolaryngol Ital. 2007 Apr; 27(2): 73 – 7.
Eccles R, Meier C, Jawad M, et al. Efficacy and safety of an antiviral Iota- Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010 Aug; 11(1): 108.
Marieb EN, Hoehn K. eds. Human Anatomy & Physiology. 7th ed. San Francisco, CA: Pearson Education, Inc.; 2007: 788 – 826.
แนวทางเวชปฏิบัติ การวินิจฉัย ดูแลรักษา และป้องกันการติดเชื้อในโรงพยาบาล กรณีโรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19) สำหรับแพทย์และบุคลากรสาธารณสุข ฉบับปรับปรุง วันที่ 22 มีนาคม 2565 [Internet]. กรมการแพทย์ [updated 2022 March 22; cited 2022 April 4]. Available from: https://covid19.dms.go.th/backend/Content/Content_File/Covid_Health/Attach/25650324144250PM_CPG%2022%E0%B8%A1%E0%B8%B5%E0%B8%99%E0%B8%B2.pdf.
DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep;100 (5): 281 – 289.
Sharma R, Agarwal M, Gupta M, et al. Clinical characteristics and differential clinical diagnosis of novel Coronavirus disease 2019 (COVID-19). In: Saxena SK eds. Coronavirus disease 2019 (COVID-19). Medical Virology: From Pathogenesis to Disease Control. Springer, Singapore; 2020. p. 55 – 70.
Qureishi A, Lee Y, Belfield K, et al. Update on otitis media - prevention and treatment. Infect Drug Resist. 2014 Jan; 7: 15 – 24.
Anderson J, Paterek E. Tonsillitis. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
ChanvatikI S, Kosiyaporn H, Lekagul A et al. Knowledge and use of antibiotics in Thailand: A 2017 national household survey. Plos One. 2019 Aug; 14(8): e0220990. https://doi.org/10.1371/journal.pone.0220990.
ซูโดอีเฟดรีน (pseudoephedrine) [Internet] กองควบคุมวัตถุเสพติด สำนักงานคณะกรรมการอาหารและยา
[updated 2020 October; cited 2022 March 3]. Available from: https://www.fda.moph.go.th/sites/Narcotics/SitePages/ViewAcademic.aspx?IDitem=5
Graf P, Enerdal J, Hallén H. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch Otolaryngol Head Neck Surg. 1999 Oct; 125(10): 1128 – 32.
Bautista DM, Siemens J, Glazer JM, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature. 2007 Jul; 448 (7150): 204 – 8.
ประกาศสํานักงานคณะกรรมการอาหารและยา เรื่อง หลักเกณฑ์ วิธีการ และเงื่อนไข ในการขายยา. [updated 2015 August 4; cited 2022 March 3]. Available from: https://papc.pharmacycouncil.org/share/file/file_1721.เงื่อนไขการขายยา.PDF
